Lv616
2556 积分 2023-05-16 加入
Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach
4天前
已完结
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
24天前
已完结
IL-18 is a key proximal mediator of contact hypersensitivity and allergen-induced Langerhans cell migration in murine epidermis
28天前
已关闭
Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond
1个月前
已关闭
783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors
1个月前
已关闭
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration
1个月前
已完结
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
1个月前
已完结
An FDA oncology analysis of antibody-drug conjugates
1个月前
已完结
皖公网安备34019202002308
